India continues to strengthen its position as the “pharmacy of the world”. According to the latest report by the Pharmaceuticals Export Promotion Council of India (Pharmexcil), India’s pharma exports grew by an impressive 9% in FY 2024-25, reaching US$28.5 billion, higher than the global average pharmaceutical export growth rate of 5%.

This strong performance reflects not only the resilience of India’s pharmaceutical industry but also its strategic importance in the global healthcare supply chain.

A Look at the Numbers

• FY 2023–24 pharma exports: USD 26.2 billion
• FY 2024–25 pharma exports: USD 28.5 billion
• Growth rate: 9% YoY
• Key markets: United States, UK, South Africa, Brazil, and Russia
• Top export segments: Generic drugs, APIs (Active Pharmaceutical Ingredients), OTC products

India remains the largest provider of generic medicines globally, accounting for 20% of global supply by volume.

Why the Surge in 2025?

Several factors contributed to this export boom:

1. Rising Demand for Generic Drugs

As developed nations continue to reduce healthcare costs, demand for affordable generics from India has soared.

2. Regulatory Approvals

In FY 2024-25, Indian pharma companies received a record number of USFDA, MHRA, and WHO-GMP approvals, enhancing global trust.

3. Strengthened Supply Chains

India’s investment in logistics and infrastructure post-COVID has resulted in more reliable global supply chains, reducing bottlenecks.

4. Government Support

Policies like PLI (Production Linked Incentive) scheme, export subsidies, and streamlined regulatory clearances have fueled export potential.

Historical Context: How Far India Has Come

If we look back a decade, India’s pharma exports were just US$15.5 billion in FY 2014-15. Since then, the sector has:

• Doubled in value
• Expanded to 200+ countries
• Gained stronghold in the global vaccine and generic market

India’s growth journey has been shaped by a relentless focus on quality, affordability and innovation.

Future Outlook: What Lies Ahead?

With a growing pipeline of biosimilars, new-age therapies and digital transformation in pharma manufacturing, India is poised to continue this momentum.

Experts estimate that India’s pharma exports could surpass USD 35 billion by 2027, owing to the following reasons:

• Demand in emerging markets like Latin America and Africa
• Growth of nutraceuticals, oncology drugs, and complex generics
• Continued regulatory harmonization and R&D investments

As Artificial Intelligence (AI) and blockchain become more integrated into pharma logistics and production, India is also preparing to lead the next generation of pharmaceutical innovation.

S V Healthcare’s Role in This Growth

At S V Healthcare, we are proud to have contributed to this historic growth trajectory. As a trusted pharmaceutical exporter and healthcare partner, we provide the following support to global companies:

• Comparator drug sourcing
• Clinical trial supply solutions
• Regulatory-compliant procurement

Our mission aligns with India’s larger vision — to make quality medicines accessible, affordable, and available to all.

Learn more about the The New Leap of Indian Pharma Export in 2025.

Conclusion

The 9% growth in India’s pharma exports is not just a number – it is a testament to the country’s growing global relevance, especially in the post-pandemic world.

As the international demand for reliable, affordable and high-quality medicines continues to grow, India is well-positioned to play a leading role in this regard.

For companies looking to partner with a trusted source of pharmaceutical excellence, S V Healthcare is ready – bringing global quality with Indian trust.

FAQs